Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO) Share Price

Price 142.50p on 11-07-2025 at 18:15:09
Change -2.75p -1.9%
Buy 144.50p
Sell 140.00p
Buy / Sell HEMO Shares
Last Trade: Buy 14.00 at 144.275p
Day's Volume: 37,988
Last Close: 142.25p
Open: 145.00p
ISIN: GB00BQVXM815
Day's Range 142.00p - 145.00p
52wk Range: 0.876p - 420.00p
Market Capitalisation: £7m
VWAP: 146.19522p
Shares in Issue: 5m

Hemogenyx (HEMO) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 14 144.275p Ordinary
16:29:28 - 11-Jul-25
Sell* 500 140.1372p Ordinary
16:26:09 - 11-Jul-25
Buy* 267 144.275p Ordinary
16:23:59 - 11-Jul-25
Buy* 681 144.275p Ordinary
16:20:52 - 11-Jul-25
Sell* 1,000 140.1372p Ordinary
16:05:22 - 11-Jul-25
Buy* 350 144.225p Ordinary
15:40:29 - 11-Jul-25
Buy* 730 144.225p Ordinary
15:27:44 - 11-Jul-25
Sell* 432 139.1678p Ordinary
14:54:41 - 11-Jul-25
Sell* 448 139.1678p Ordinary
14:07:11 - 11-Jul-25
Buy* 60 144.225p Ordinary
12:44:35 - 11-Jul-25
See more Hemogenyx trades

Hemogenyx (HEMO) Share Price History

Time period:
to
Date Open High Low Close Volume
11th Jul 2025 (Fri) 145.00 145.00 142.00 142.25 37,988
10th Jul 2025 (Thu) 150.00 156.50 145.00 145.00 38,066
9th Jul 2025 (Wed) 153.25 153.25 153.25 153.25 15,568
8th Jul 2025 (Tue) 153.25 153.25 153.25 153.25 14,505
7th Jul 2025 (Mon) 150.00 150.00 150.00 153.25 10,872
4th Jul 2025 (Fri) 153.25 153.25 153.25 153.25 91,796
3rd Jul 2025 (Thu) 156.50 156.50 156.50 153.25 8,271
2nd Jul 2025 (Wed) 153.25 153.25 153.25 153.25 30,048
1st Jul 2025 (Tue) 153.25 153.25 153.25 153.25 25,856
30th Jun 2025 (Mon) 153.25 153.25 153.25 153.25 42,813
27th Jun 2025 (Fri) 150.00 150.00 150.00 153.25 102,667
26th Jun 2025 (Thu) 152.25 154.25 152.25 154.25 37,398
25th Jun 2025 (Wed) 165.00 165.00 154.00 152.25 64,829
24th Jun 2025 (Tue) 168.50 168.50 168.50 169.25 8,271
23rd Jun 2025 (Mon) 177.50 177.50 177.50 169.75 21,123
20th Jun 2025 (Fri) 170.00 170.00 170.00 172.25 4,852
19th Jun 2025 (Thu) 173.75 175.00 173.75 175.00 3,151
18th Jun 2025 (Wed) 170.50 170.50 170.00 173.75 24,386
17th Jun 2025 (Tue) 175.00 175.00 175.00 172.25 12,535
16th Jun 2025 (Mon) 175.00 175.00 173.00 172.25 27,013
13th Jun 2025 (Fri) 177.25 177.50 177.25 177.50 1,612
12th Jun 2025 (Thu) 175.50 175.50 175.50 177.25 1,837
See more Hemogenyx price history

Hemogenyx (HEMO) Regulatory News

Date Source Headline
30th Jun 2025 7:00 am RNS Total Voting Rights
17th Jun 2025 7:00 am RNS Clearance to Proceed with Pediatric Expansion
3rd Jun 2025 2:02 pm RNS Placing to Raise £451,250 and Director’s Dealing
3rd Jun 2025 7:00 am RNS Second Patient Passes Initial Safety Tests
30th May 2025 3:14 pm RNS Total Voting Rights
29th May 2025 2:06 pm RNS Result of AGM
14th May 2025 7:00 am RNS-R Pediatric Amendment to Clinical Protocol
13th May 2025 7:00 am RNS AGM Correction
8th May 2025 7:00 am RNS Placing to Raise £451,250 and Director’s Dealing
2nd May 2025 4:24 pm RNS Notice of AGM
See more Hemogenyx regulatory news

Hemogenyx (HEMO) Share News

TRADING UPDATES: Safestay mulls asset sale; Sound Energy inks 2 deals

17th Jun 2025 15:48

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Valereum invests in Blubird; Hemogenyx raises funds

3rd Jun 2025 22:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

22nd May 2025 14:05

Read More

IN BRIEF: Hemogenyx expands trial to include paediatric patients

14th May 2025 14:28

Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology. Read More

TRADING UPDATES: GlobalData suspends buyback; Hemogenyx trial progress

2nd May 2025 22:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more Hemogenyx news
FTSE 100 Latest
Value8,941.12
Change-34.54

Login to your account

Forgot Password?

Not Registered